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Abstract: From 1963 to the present, many reviews of antimalarials for use in
dermatology have mentioned the speeial sensitivity of ehildren to these drugs.
Fatal reactions have been limited to aeeidental or intentional overdosage and two
instanees of IM injection. While 1 gni of ehloroquine ean produee fatal reaetion
in very young ehildren. analysis of published and unpublished eases show that
adults exhibit a similar sensitivity when eompared on a mg/kg basis. This infor-
mation should eneourage a physician to use antimalarials where appropriate, but
speeial precaution should be taken to prevent poisoning.
Antimalarials (AM) are not commonly used in thc
treatment of children with skin disease. There are,
however, several situations in which AM may be
most useful (1-6). Isaacson. Elgart. and Turner list
over 15 conditions in which antimalarials may be of
some therapeutic benefit (3). Of these, discoid lupus
er\thematosus and polymorphus light eruption oecur
with some frequency in ehildren. In addition. Isaac-
son et ak note that antimalarials have been anec-
dotally reported to be effective in scleroderma.
disseminated granuloma annulare. sarcoid and epi-
dermolysis buUosa. conditions that are aiso seen oc-
casionally in the pediatrie population. There are. of
course, other nondermatologic conditions for which
antimalarials play a substantial part in therapy. There
are numerous reviews attesting to the efficacy of
antimalarials in the treatment of rheumatoid atlhritis.
Antimalarials are still recommended for the prophy-
laxis and treatment of malaria for both travelers and
those who are indigenous to the malaria belts of the
world (7). In addition, many authors consider quin-
acrine to be the treatment of choice for giardiasis,
whieh is a not uncommon enteric parasitic infection
of ehildren and young adults (8. 9). Finally, the op-
tical isomer of quinine—quinidinc—is occasionally
used for the treatment of cardiac arrhythmias in chil-
dren (10).
Although I do not use antimalarials commonly in
my pediatric practice. I was aware that there are
definite indications for their use in the population
and have prescribed them many times without sig-
nificant adverse reaction. Consequently I have been
surprised to read, during the past four years, that
many authors consider antimalarials eontraindicated
in the treatment of children with skin disease (1-6).
Four reviews in the past two years mentioned that
antimalarials are exceptionally toxic in children (3 -
6), and two of them have concluded that these drugs
are contraindicated tor use in this population (3, 6).
I was even more surprised to find that this position
was not a new one, but had been mentioned in re-
views of antimalarials sinee 1963. At that time, Rees
and Maibach noted that choloroquine vvas excep-
tionally toxic in children and that deaths had oc-
curred from as little as 7? mg (I). In addition. Sams
in his 1976 review of antimalarials came to a similar
conclusion, suggesting that they are contraindicated
in children (2).
Because of this paradox—many dermatologists
considering antimalarials contraindicated, but other
physicians using them for parasitic diseases, rheu-
matoid arthritis, and a diversity of cutaneous con-
ditions, etc.—I conducted a literature review on this
subject and present these results to you.
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M a n \ a n i m i a l a i l a l s . siieli as ijiiinaLTitic. c h i o r o -
quiiie, and hydmxychloroquitic. have a 4-iuiiino
qumolinc as their basic nucleus (Fig. 1 i (I f>), Thc
lirsi mombci" ol this group to be used in thc trcattnenl
ot disease was quinine, whieli has a well-known his-
toiy in the prevention and therapy of malaria. In
1894 Payne deseribed the etTeetiveness o! quinine m
the treattnent o\' lupus erythetiiatosus. Other anti-
malarials were synthesized by Gemian biochemists
Uuritig and after World War I. which caused inter-
ruption of notrnal sourees of supply of quinine.
Quinaerine (Atabrinc and others) and ehloroquine
(Aralen and others) were the results of these elfoiis.
Further modifications such as hydroxychloroquinc
(Plaquenil) were developed in the 1950s and soon
beeame commonly used in the treatment of several
eonnective tissue diseases such as lupus erythema-
tosus and rheumatoid anhritis.
There is no evidence suggesting that children have
an increased incidence of subacute and chronic tox-
icity for antimalarials. Nearly all reports focus on
accidental or intentional overdosage. Cann and Ver-
hulst were the first to report fatal poisonings from
antimalarials in ehildren ( I I ) . These 3 fatal cases
occurred in 1-3-year-old children who had taken ap-
proximately 1-3.5 grams of ehloroquine orally. Toxic
symptoms appeared 1 to 3 hours later and eonsisted
of convulsions, apnea, and eardiae arrest. Similar
groups of 1-2 ehildren contmued to be published
during the mid and late 1960s (12-15). Most ofthe
poisonings were due to ehloroquine. but at least one
occurred after the oral ingestion of quinine (15). In
1974. DeMaio and Henry published a general review
of ehloroquine poisoning (16). These authors
searched the files of the Atmed Forces Institute of
Patbology for all fatal cases of ehloroquine poison-
ing and detailed 27 case reports. Of this group. 6




Figure 1. Nucleus of many antimalarials.
years. In 3 ol the cases, the amount (jt thc drug
ingested was unknown, and in the other 3 it ranged
trom 1 to 2.5 grams. The data available for toxic
reactions in the adults in this series indicated that
they succumbed lo a dose ranging from as few as
10 ehloroquine tablets, to approximately 50. Based
on Ihis information, the authors conclude that "chil-
dren . . . appear to be especially sensitive to this
drug," If. however, the number of tablets necessary
to produce a toxic reaction in children is compared
to that of adults on a tablet or mg/kg basis, then this
disparity ceases to exist. A 2-year-old child (average
weight 14 kilograms) succumbed to I gm of chloro-
quine for a lethal dose of 70 mg/kg. while a mini-
mum of ten 500 mg tablets was needed to produce
a fatal result in adult servicemen (average weight 80
kilograms) for a lethal dose of 60 mg/kg.
From 1974 until the present time, poisonings frotn
antimalarials continue to he reported, usually from
accidental or intentional overdosage (12-19). There
are, however, two examples where ehloroquine had
been used therapeutically with a fatal outcome (19-
20). These reports described the intramuscular iti-
jeetion of ehloroquine for the treatment of maiaria
in very young ehildren.
In addition to these published case reports, there
are 4 unpublished reports contained in the FDA's
toxicology files (21). In these situations, the patient̂
ranged in age from 2 to 17 years, with a minimum
toxie dose being 2 gm of ehloroquine. One patienl
in this series was 17 years of age and took an un-
known number of hydroxychloroquine tablets.
There are certainly many more examples of toxiv
reaction to orally ingested antimalarials. but these
patients are usually blended in with general review^
of poisoning (22, 23). Specific data about drug dose
age of the patient, etc. are usually not given.
Toxic reactions to antimalarials occur quite rap-
idly after overdose. In pan. this is because this group
of dtngs is rapidly and completely absorbed in the
upper portion of the gastrointestinal tract. Nausea
and vomiting are common early symptoms and are
also seen commonly in children and adults who ha\e
taken otherwise safe, therapeutie doses. Several
studies suggest that younger children are more su>-
ceptable to gastric itTitation from antimalarials thar,
are older children (7. 24). More advanced cases ol
poisoning resemble examples of salicylism with tin-
nitus and vertigo being common symptoms. As poi-
soning progresses, generalized seizures occur,
followed by cardiac and respiratory arrest. Appar-
ently the fatal etTects ol" AM are in major part related
to their ability to depress myoeardial exeitability.
There is no specific antidote for antimalarial over-
dose, but immediate gastric emesis and lavage would
seetn most appropriate. Peritoneal dialysis has been
used in one childhood poisoning, but without pro-
notinccd beneficial effect ( 18),
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